Details of the Drug

General Information of Drug (ID: DMC3JST)

Drug Name

Clorazepate

Synonyms

Chlorazepate; Tranxene; Cchlorazepic acid; Chlorazepic acid; Clorazepate dipotassium; Clorazepic acid; Clorazepic acid [BAN]; Gen-xene; Novo-Clopate; Tranxene (Cherazepate dipotasium); Tranxene (TN); Novo-Clopate (TN); (Chloromethyl)(dimethyl)(tridecyloxy)silane; 7-Chloro-2,3-dihydro-2,2-dihydroxy-5-phenyl-1H-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid; 7-chloro-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Alcohol withdrawal	N.A.	Approved	[1]
Anxiety	N.A.	Approved	[1]
Anxiety disorder	6B00-6B0Z	Approved	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Hypnotics and Sedatives

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

314.72

Logarithm of the Partition Coefficient (xlogp)

3.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 91% of drug becomes completely available to its intended biological destination(s) [4]
Clearance: The drug present in the plasma can be removed from the body at the rate of 1.1 mL/min/kg [5]
Elimination: 0.5% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 40 - 50 hours [5]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.44685 micromolar/kg/day [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.2 L/kg [5]

Chemical Identifiers

Formula: C16H11ClN2O3
IUPAC Name: 7-chloro-2-oxo-5-phenyl-1,3-dihydro-1,4-benzodiazepine-3-carboxylic acid
Canonical SMILES: C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O
InChI: InChI=1S/C16H11ClN2O3/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12/h1-8,14H,(H,18,20)(H,21,22)
InChIKey: XDDJGVMJFWAHJX-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2809
ChEBI ID: CHEBI:3761
CAS Number: 23887-31-2
DrugBank ID: DB00628
TTD ID: D0P3JU
INTEDE ID: DR0358
ACDINA ID: D00143

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Translocator protein (TSPO)	TTPTXIN	TSPO_HUMAN	Modulator	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Clorazepate (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Sodium bicarbonate	DMMU6BJ	Minor	Altered absorption of Clorazepate due to GI dynamics variation caused by Sodium bicarbonate.	Acidosis [5C73]	[9]
Oliceridine	DM6MDCF	Major	Additive CNS depression effects by the combination of Clorazepate and Oliceridine.	Acute pain [MG31]	[10]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Clorazepate caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[11]
Clarithromycin	DM4M1SG	Moderate	Decreased metabolism of Clorazepate caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Clorazepate caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Dihydrocodeine	DMB0FWL	Major	Additive CNS depression effects by the combination of Clorazepate and Dihydrocodeine.	Chronic pain [MG30]	[10]
Olopatadine	DMKMWQG	Moderate	Additive CNS depression effects by the combination of Clorazepate and Olopatadine.	Conjunctiva disorder [9A60]	[14]
Propofol	DMB4OLE	Moderate	Additive CNS depression effects by the combination of Clorazepate and Propofol.	Corneal disease [9A76-9A78]	[15]
Alfentanil	DMVO0UB	Major	Additive CNS depression effects by the combination of Clorazepate and Alfentanil.	Corneal disease [9A76-9A78]	[10]
Remifentanil	DMZTXCH	Major	Additive CNS depression effects by the combination of Clorazepate and Remifentanil.	Corneal disease [9A76-9A78]	[10]
Mifepristone	DMGZQEF	Moderate	Decreased metabolism of Clorazepate caused by Mifepristone mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[16]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Clorazepate caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[17]
Ethanol	DMDRQZU	Moderate	Additive CNS depression effects by the combination of Clorazepate and Ethanol.	Cystitis [GC00]	[18]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Clorazepate caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[19]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Clorazepate caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[20]
Nefazodone	DM4ZS8M	Moderate	Decreased metabolism of Clorazepate caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[21]
Esketamine	DMVU687	Moderate	Additive CNS depression effects by the combination of Clorazepate and Esketamine.	Depression [6A70-6A7Z]	[14]
SODIUM CITRATE	DMHPD2Y	Minor	Altered absorption of Clorazepate due to GI dynamics variation caused by SODIUM CITRATE.	Discovery agent [N.A.]	[9]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Clorazepate caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Fosphenytoin	DMOX3LB	Moderate	Increased metabolism of Clorazepate caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Clorazepate caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[16]
Ethotoin	DMXWOCP	Moderate	Increased metabolism of Clorazepate caused by Ethotoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[23]
Boceprevir	DMBSHMF	Moderate	Decreased metabolism of Clorazepate caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[24]
Telaprevir	DMMRV29	Moderate	Decreased metabolism of Clorazepate caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[25]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Clorazepate caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[16]
Rifampin	DMA8J1G	Minor	Increased metabolism of Clorazepate caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[26]
Rifapentine	DMCHV4I	Moderate	Increased metabolism of Clorazepate caused by Rifapentine mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[27]
Fosamprenavir	DM4W9B3	Moderate	Decreased metabolism of Clorazepate caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Clorazepate caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[29]
Saquinavir	DMG814N	Moderate	Decreased metabolism of Clorazepate caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[30]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Clorazepate caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[31]
Didanosine	DMI2QPE	Minor	Altered absorption of Clorazepate due to GI dynamics variation caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[9]
Amprenavir	DMLMXE0	Moderate	Decreased metabolism of Clorazepate caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[28]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Clorazepate caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[32]
Conivaptan	DM1V329	Moderate	Decreased metabolism of Clorazepate caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[33]
Probenecid	DMMFWOJ	Minor	Decreased metabolism of Clorazepate caused by Probenecid.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[34]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Clorazepate caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[35]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Clorazepate caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[16]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Clorazepate caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[36]
Idelalisib	DM602WT	Moderate	Decreased metabolism of Clorazepate caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[37]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Clorazepate caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[38]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Clorazepate caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[16]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Clorazepate and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[35]
Lasmiditan	DMXLVDT	Moderate	Additive CNS depression effects by the combination of Clorazepate and Lasmiditan.	Migraine [8A80]	[39]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Clorazepate caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[40]
Flibanserin	DM70DTN	Moderate	Additive CNS depression effects by the combination of Clorazepate and Flibanserin.	Mood disorder [6A60-6E23]	[14]
Thalidomide	DM70BU5	Moderate	Additive CNS depression effects by the combination of Clorazepate and Thalidomide.	Multiple myeloma [2A83]	[14]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Clorazepate caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[41]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Clorazepate caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[30]
Modafinil	DMYILBE	Minor	Increased metabolism of Clorazepate caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[42]
Teduglutide	DMYOAKS	Moderate	Altered absorption of Clorazepate caused by Teduglutide.	Neonatal malabsorption syndrome [KB89]	[43]
Levomethadyl Acetate	DM06HG5	Major	Additive CNS depression effects by the combination of Clorazepate and Levomethadyl Acetate.	Opioid use disorder [6C43]	[10]
Apraclonidine	DMO4PVE	Moderate	Additive CNS depression effects by the combination of Clorazepate and Apraclonidine.	Optic nerve disorder [9C40]	[44]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Clorazepate caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[45]
Pentazocine	DM1XBHS	Major	Additive CNS depression effects by the combination of Clorazepate and Pentazocine.	Pain [MG30-MG3Z]	[10]
Dextropropoxyphene	DM23HCX	Major	Additive CNS depression effects by the combination of Clorazepate and Dextropropoxyphene.	Pain [MG30-MG3Z]	[46]
Oxymorphone	DM65AGJ	Major	Additive CNS depression effects by the combination of Clorazepate and Oxymorphone.	Pain [MG30-MG3Z]	[10]
Levorphanol	DMGS80V	Major	Additive CNS depression effects by the combination of Clorazepate and Levorphanol.	Pain [MG30-MG3Z]	[10]
Dezocine	DMJDB0Y	Major	Additive CNS depression effects by the combination of Clorazepate and Dezocine.	Pain [MG30-MG3Z]	[10]
Nalbuphine	DMOSQGU	Major	Additive CNS depression effects by the combination of Clorazepate and Nalbuphine.	Pain [MG30-MG3Z]	[10]
Buprenorphine	DMPRI8G	Major	Additive CNS depression effects by the combination of Clorazepate and Buprenorphine.	Pain [MG30-MG3Z]	[47]
Hydrocodone	DMQ2JO5	Major	Additive CNS depression effects by the combination of Clorazepate and Hydrocodone.	Pain [MG30-MG3Z]	[10]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Clorazepate caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[48]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Clorazepate caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[13]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Clorazepate caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[49]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Clorazepate and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[50]
Fentanyl	DM8WAHT	Major	Additive CNS depression effects by the combination of Clorazepate and Fentanyl.	Sensation disturbance [MB40]	[10]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Clorazepate caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[16]
Armodafinil	DMGB035	Minor	Increased metabolism of Clorazepate caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[42]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Clorazepate caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[51]
Tizanidine	DMR2IQ4	Moderate	Additive CNS depression effects by the combination of Clorazepate and Tizanidine.	Tonus and reflex abnormality [MB47]	[14]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Clorazepate and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[50]
Tacrolimus	DMZ7XNQ	Moderate	Increased plasma concentrations of Clorazepate and Tacrolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[50]
Amiodarone	DMUTEX3	Minor	Potentiate the pharmacologic effects by the combination of Clorazepate and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[52]
-----------


⏷ Show the Full List of 74 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
FD&C blue no. 2	E00446	2723854	Colorant
Potassium chloride	E00074	4873	Tonicity agent
FD&C red no. 3	E00629	Not Available	Colorant
Magnesium oxide	E00232	14792	Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate	E00208	11177	lubricant
Potassium carbonate	E00211	11430	Alkalizing agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
--------------------


⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Clorazepate 15 mg tablet	15 mg	Oral Tablet	Oral
Clorazepate 3.75 mg tablet	3.75 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Clorazepate FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7548).
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8	In vitro drug allergy detection system incorporating human liver microsomes in chlorazepate-induced skin rash: drug-specific proliferation associated with interleukin-5 secretion. Br J Dermatol. 2001 Feb;144(2):316-20.
9	Greenblatt DJ, Allen MD, MacLaughlin DS, Harmatz JS, Shader RI "Diazepam absorption: effect of antacids and food." Clin Pharmacol Ther 24 (1978): 600-9. [PMID: 699484]
10	US Food and Drug Administration "FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines requires its strongest warning.".
11	Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
12	Mattila MJ, Idanpaanheikkila JJ, Tornwall M, Vanakoski J "Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance." Pharmacol Toxicol 73 (1993): 180-5. [PMID: 8265524]
13	Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
14	Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
15	McClune S, McKay AC, Wright PM, et al "Synergistic interaction between midazolam and propofol." Br J Anaesth 69 (1992): 240-5. [PMID: 1389840]
16	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
17	Lilja JJ, Kivisto KT, Neuvonen PJ "Grapefruit juice-simvastatin interaction: Effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors." Clin Pharmacol Ther 64 (1998): 477-83. [PMID: 9834039]
18	Divoll M, Greenblatt DJ, Lacasse Y, Shader RI "Benzodiazepine overdosage: plasma concentrations and clinical outcome." Psychopharmacology (Berl) 73 (1981): 381-3. [PMID: 6789361]
19	Product Information. Prevymis (letermovir). Merck &amp Company Inc, Whitehouse Station, NJ.
20	Dresser GK, Spence JD, Bailey DG "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition." Clin Pharmacokinet 38 (2000): 41-57. [PMID: 10668858]
21	Barbhaiya RH, Shukla UA, Kroboth PD, Greene DS "Coadministration of nefazodone and benzodiazepines: 2. a pharmacokinetic interaction study with triazolam." J Clin Psychopharmacol 15 (1995): 320-6. [PMID: 8830062]
22	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
23	Murphy A, Wilbur K "Phenytoin-diazepam interaction." Ann Pharmacother 37 (2003): 659-63. [PMID: 12708941]
24	Product Information. Victrelis (boceprevir). Schering-Plough Corporation, Kenilworth, NJ.
25	Product Information. Incivek (telaprevir). Vertex Pharmaceuticals, Cambridge, MA.
26	Ochs HR, Greenblatt DJ, Roberts GM, Dengler HJ "Diazepam interaction with antituberculosis drugs." Clin Pharmacol Ther 29 (1981): 671-8. [PMID: 7214796]
27	Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
28	Product Information. Agenerase (amprenavir). Glaxo Wellcome, Research Triangle Pk, NC.
29	Bailey DG, Dresser GK "Natural products and adverse drug interactions." Can Med Assoc J 170 (2004): 1531-2. [PMID: 15136542]
30	Cerner Multum, Inc. "Australian Product Information.".
31	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
32	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
33	Gunston GD, Mehta U "Potentially serious drug interactions with grapefruit juice." S Afr Med J 90 (2000): 41. [PMID: 10721388]
34	Abernethy DR, Greenblatt DJ, Ameer B, Shader RI "Probenecid impairment of acetaminophen and lorazepam clearance: direct inhibition of ether glucuronide formation." J Pharmacol Exp Ther 234 (1985): 345-9. [PMID: 4020675]
35	Gilman AG, Rall TW, Nies AS, Taylor P, eds. "Goodman and Gilman's the Pharmacological Basis of Therapeutics. 8th ed." New York, NY: Pergamon Press Inc. (1990):.
36	Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
37	Bailey DG, Malcolm J, Arnold O, Spence JD "Grapefruit juice-drug interactions." Br J Clin Pharmacol 46 (1998): 101-10. [PMID: 9723817]
38	Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
39	Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
41	Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
42	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
43	Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ "Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice." Clin Pharmacol Ther 58 (1995): 127-31. [PMID: 7648762]
44	Product Information. Alphagan (brimonidine ophthalmic). Allergan Inc, Irvine, CA.
45	EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
46	Hansen BS, Dam M, Brandt J, et al "Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man." Acta Neurol Scand 61 (1980): 357-67. [PMID: 6998251]
47	Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ "Benzodiazepine use during buprenorphine treatment for opioid dependence: clinical and safety outcomes." Drug Alcohol Depend 132 (2013): 580-6. [PMID: 23688843]
48	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
49	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
50	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
51	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
52	Kerin NZ, Aragon E, Faitel K, Frumin H, Rubenfire M "Long-term efficacy and toxicity of high- and low-dose amiodarone regimens." J Clin Pharmacol 29 (1989): 418-23. [PMID: 2661600]